{"id":"NCT01730040","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","officialTitle":"A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2014-04","completion":"2014-05","firstPosted":"2012-11-21","resultsPosted":"2015-08-31","lastUpdate":"2015-08-31"},"enrollment":355,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["REGN727/SAR236553"]},{"type":"DRUG","name":"Atorvastatin","otherNames":[]},{"type":"DRUG","name":"Ezetimibe","otherNames":["Ezetrol"]},{"type":"DRUG","name":"Rosuvastatin","otherNames":["Crestor"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Atorvastatin 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"Ezetimibe 10 mg + Atorvastatin 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg","type":"EXPERIMENTAL"},{"label":"Atorvastatin 80 mg","type":"ACTIVE_COMPARATOR"},{"label":"Rosuvastatin 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"Ezetimibe 10 mg + Atorvastatin 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Atorvastatin 40 mg","deltaMin":-5,"sd":4.6},{"arm":"Ezetimibe 10 mg + Atorvastatin 20 mg","deltaMin":-20.5,"sd":4.7},{"arm":"Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg","deltaMin":-44.1,"sd":4.5},{"arm":"Atorvastatin 80 mg","deltaMin":-4.8,"sd":4.2},{"arm":"Rosuvastatin 40 mg","deltaMin":-21.4,"sd":4.2},{"arm":"Ezetimibe 10 mg + Atorvastatin 40 mg","deltaMin":-22.6,"sd":4.3},{"arm":"Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg","deltaMin":-54,"sd":4.3}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.0001"},{"comp":"OG001 vs OG002","p":"= 0.0004"},{"comp":"OG003 vs OG006","p":"< 0.0001"},{"comp":"OG004 vs OG006","p":"< 0.0001"},{"comp":"OG005 vs OG006","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":97,"countries":["United States","Australia","Canada","France","Germany","Italy","Mexico","Spain","United Kingdom"]},"refs":{"pmids":["34298554","30183102","27777279","26030325","25269777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":57},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Nausea","Nasopharyngitis","Back pain"]}}